Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 14/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 14/20 | 1.00 |
| ▸ | PDE5A | O76074 | 8/20 | 1.00 |
| ▸ | PDE1A | P54750 | 8/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 8/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307929 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20756030 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5607953 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7160159 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7495374 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7818726 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7682562 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7673788 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7491632 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7491635 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| EP-0785789-B1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | PFIZER (FR) | 2002-09-11 | — | — | EP | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617777-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | TANABE SEIYAKU CO., LTD. | 2008-02-07 | — | — | US | disclosed |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | TANABE SEIYAKU CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | TANABE SEIYAKU CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| EP-1706118-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005067929-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON A SCOPINEESTER AND NICOTINAMIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-6365585-B1 | USED AS ANTI-INFLAMMATORIES, ANTI-ALLERGICS, BRONCHODILATORS OR ANTI-ASTHMATICS AND ARE DEVOID OF DIGESTIVE OR CARDIAC SIDE-EFFECTS | WARNER-LAMBERT COMPANY | 2002-04-02 | — | — | US | disclosed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | PDE4A 4881/4885PDE4B 4880/4885PDE4C 4878/4885 |
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | PDE4A, PDE7A, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 7/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PDE4A 4097/4885PDE4B 4018/4885PDE4C 4207/4885 |
| US-12617777-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR3 | PDE4A 2887/4885PDE4B 3692/4885PDE4C 3821/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | PDE4A 4776/4885PDE4B 4760/4885PDE4C 4800/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | PDE4A 3749/4885PDE4B 3747/4885PDE4C 4029/4885 |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885 |
| US-20260137709-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR3C1, NR3C2, NR4A1 | PDE4A 1922/4885PDE4B 2361/4885PDE4C 1960/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | PDE4A 701/4885PDE4B 713/4885PDE4C 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.